Research Article

Associations between β-Blocker Therapy at Discharge and Long-Term Follow-Up Outcomes in Patients with Unstable Angina Pectoris

Table 2

Laboratory test results and echocardiographic and angiographic characteristics.

Before PS matchAfter PS match
β-Blocker (-) N = 1801β-Blocker (+) N = 3790 valueβ-Blocker (-) N = 1786β-Blocker (+) N = 1786 value

Laboratory values
WBC (×109/L)6.1 (5.2, 7.3)6.4 (5.4, 7.5)<0.0016.2 (5.2, 7.3)6.3 (5.3, 7.4)0.011
Hemoglobin (g/L)135.6 ± 15.9135.4 ± 16.80.648135.6 ± 15.9135.0 ± 17.30.245
PLT (×1012/L)211.0 (179.0, 248.0)215.0 (180.0, 254.0)0.021211.0 (179.0, 249.0)211.0 (177.0, 250.0)0.988
HsCRP (mg/L)1.3 (0.6, 2.5)1.6 (0.7, 3.3)<0.0011.3 (0.6, 2.5)1.5 (0.6, 3.3)0.001
FBG (mmol/l)5.8 (5.0, 7.5)6.1 (5.1, 8.0)<0.0015.8 (5.0, 7.5)5.9 (5.0, 7.7)0.432
HbA1C (%)6.0 (5.6, 6.8)6.2 (5.7, 7.2)<0.0016.0 (5.6, 6.8)6.1 (5.6, 6.9)0.294
ALT (U/L)17.0 (12.0, 24.0)18.0 (13.0, 26.0)<0.00117.0 (12.8, 24.0)17.0 (13.0, 25.0)0.211
Creatinine (μmol/L)75.3 (64.9, 86.1)75.9 (65.5, 87.9)0.35475.2 (64.9, 86.1)75.4 (65.5, 86.9)0.318
eGFR (mL/min/1.73 m2)156.6 (124.1, 191.9)153.3 (122.6, 190.9)0.084156.6 (124.0,192.0)155.0 (124.2,190.5)0.594
TC (mmol/L)4.1 (3.5, 4.8)4.0 (3.4, 4.8)0.1654.1 (3.5, 4.8)4.1 (3.4, 4.8)0.287
TG (mmol/L)1.3 (1.0, 1.9)1.4 (1.0, 2.0)<0.0011.3 (1.0, 1.9)1.3 (1.0, 1.9)0.734
HDL (mmol/L)1.1 (0.9, 1.3)1.1 (0.9, 1.2)0.1971.1 (0.9, 1.3)1.1 (0.9, 1.2)0.978
LDL (mmol/L)2.3 (1.8, 2.8)2.2 (1.8, 2.7)0.0742.3 (1.8, 2.8)2.2 (1.8, 2.7)0.127

Echocardiographic values
LA (cm)3.7 ± 0.43.7 ± 0.50.0913.7 ± 0.43.7 ± 0.50.406
LVEDD (cm)5.0 (4.7, 5.3)5.0 (4.7, 5.3)0.9125.0 (4.7, 5.3)5.0 (4.7, 5.3)0.330
LVESD (cm)3.1 (2.9, 3.4)3.1 (2.9, 3.4)0.0763.1 (2.9, 3.4)3.1 (2.9, 3.4)0.086
LVEF (%)0.67 (0.64, 0.71)0.67 (0.63, 0.70)0.0260.67 (0.64, 0.71)0.67 (0.63, 0.70)0.129
LVEF (40–49) (%)48 (2.7)186 (4.9)<0.00148 (2.7)69 (3.9)0.048
LVEF (<40) (%)10 (0.6)58 (1.5)<0.00110 (0.6)24 (1.3)0.039
LVFS (%)0.38 (0.35, 0.40)0.37 (0.34, 0.40)0.0250.38 (0.35, 0.40)0.37 (0.35,0.40)0.138

Angiography values
LM (%)164 (9.1)402 (10.6)0.082161 (9.0)183 (10.2)0.212
Multivessels (%)1379 (76.6)3155 (83.2)<0.0011368 (76.6)1446 (81.0)0.001
CTO (%)140 (7.8)404 (10.7)0.001140 (7.8)181 (10.1)0.016
PCI (%)957 (53.1)2277 (60.1)<0.001950 (53.2)1087 (60.9)<0.001

Medication used at discharge
Antiplatelet agent (%)1670 (92.7)3727 (98.3)<0.0011657 (92.8)1757 (98.4)<0.001
ACEI/ARB (%)798 (44.3)1984 (52.3)<0.001796 (44.6)920 (51.5)<0.001
Statins (%)1582 (87.8)3508 (92.6)<0.0011570 (87.9)1672 (93.6)<0.001

Data are presented as mean ± SD, IQR, or n (%). WBC, white blood cells; PLT, platelet count; hsCRP, hypersensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbAIC, glycosylated hemoglobin; ALT, alanine aminotransferase; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LVFS, left ventricular fraction shortening; LM, left main trunk; CTO, chronic total occlusions; PCI, percutaneous coronary intervention; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.